אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל
inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.
אונדאנסטרון - פרזניוס
neopharm (israel) 1996 ltd - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:for the mangement of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population:for the mangement of chemotherapy-induced nausea and vomiting (cinv) in children aged ? 6 months, and for the prevention and treatment of ponv in children aged ? 2 years.
אודנטרון
k.s.kim international (sk- pharma) ltd., israel - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults: odnatron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. odnatron is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population: odantron is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.
גרניסטרון טבע
teva pharmaceutical indust.ltd - granisetron as hydrochloride 3 mg / 3 ml - solution for infusion - granisetron - for the prevention and control of nausea and vomiting induced by cytostatic therapy (chemotherapy and radiotherapy).
נורדיטרופין 15 מג
novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 10 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.
נורדיטרופין 10 מג
novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 10 mg / 1.5 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.
נורדיטרופין 5 מג
novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 3.3 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.
סומטולין אוטוג'ל 60 מג
medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 60 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.
סומטולין אוטוג'ל 90 מג
medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 90 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.
סומטולין אוטוג'ל 120 מג
medison pharma ltd - lanreotide as acetate - תמיסה להזרקה - lanreotide as acetate 120 mg/dose - lanreotide - lanreotide - somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of growth hormone (gh) and/or insulin like growth factor-1 (igf-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent .the goal of treatment in acromegaly is to reduce gh and igf-1 levels and where possible to normalize these values. somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.